Compare H2O America (HTO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Novartis AG — how do they compare? H2O America trades at $58.56 (market cap $2.43B), while Novartis AG trades at $143.31 (market cap $268.57B). The key difference: Novartis AG is far larger — about 110.5× H2O America's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Novartis AG for 82 Days on average.
| HTO | NVS | |
|---|---|---|
Market Cap | $2.43B | $268.57B |
Volume | 593,883 | 1,532,573 |
Sector | Utilities | Health |
52-Week High | $65.43 | $168.62 |
52-Week Low | $44.44 | $121.80 |
Typical Hold Time | 40 Days | 82 Days |
Enterprise Value | $4.22B | $309.89B |
Dividend Yield | 3.03% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $57.98, down 0.34% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 12.91% net margin and 6.46% ROE, supported by recent acquisitions in Texas water utilities. Analyst consensus remains strongly bullish with 83% buy ratings and $66.50 price target, representing 15% upside potential from current levels.
The stock offers attractive dividend yield with recent $0.44 dividend declaration, but faces execution risks from acquisition integration and negative cash flow from investing activities. Technical indicators show mixed signals with oversold RSI readings conflicting with bearish moving averages, creating potential entry opportunity for long-term investors.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
